At EuroPCR in Paris, investigators of the controversial ORBITA trial presented two previously unreported benefits of percutaneous coronary intervention (PCI) for the study population.

PARIS, May 22, 2018 — HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most common form of heart disease, when compared to other commonly used non-invasive cardiac tests.

Percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) was associated with a 54 percent reduction in the composite endpoint of death, myocardial infarction and urgent revascularization when compared to medical therapy alone, according to five-year data from the FAME 2 trial.

DUBLIN and BOSTON — May 11, 2018 — Medtronic plc (NYSE:MDT) today announced new clinical study results demonstrating that an investigational algorithm, utilizing the accelerometer signal in the Micra(TM) Transcatheter Pacing System (TPS) may restore AV synchrony, improving cardiac function in patients with sinus rhythm and atrioventricular (AV) block.

Catheter ablation was found to be superior to optimal drug therapy for the primary treatment of atrial fibrillation (AFib) in the randomized CABANA trial presented May 10 at the Heart Rhythm Society’s annual scientific sessions in Boston. However, there was a caveat.

An expert consensus document published May 2 in the Journal of the American College of Cardiology offers recommendations for limiting radiation exposure to both patients and medical personnel during cardiovascular imaging procedures.

Vienna, VA (April 25, 2017) — James K. Min, MD, FSCCT, has been selected for a five-year term as the new editor-in-chief of the Journal of Cardiovascular Computed Tomography (JCCT). He in turn has named Todd C. Villines, MD, FSCCT, as executive editor along with Gudrun Feuchtner, MD.